Genus plc is a British-based business selling elite genetics and other products manufactured using biotechnology to cattle and pig farmers. It is headquartered in Basingstoke and is a constituent of the FTSE 250 Index.
Company type | Public |
---|---|
ISIN | GB0002074580 |
Industry | Biotechnology |
Founded | 1933 |
Headquarters | Basingstoke, Hampshire, UK |
Key people | Iain Ferguson, Chairman[1] Jorgen Kokke, CEO[1] |
Revenue | £689.7 million (2023)[2] |
£40.5 million (2023)[2] | |
£31.8 million (2023)[2] | |
Website | www |
History
editThe business has its origins in the former Breeding & Production Division of the Milk Marketing Board which was established in 1933 and broken up in 1994.[3] In 1999 Genus acquired ABS Global, a company founded by J.R. Prentice in the US as the American Breeders Service in 1941 selling the semen of cattle.[4] In 2005 Genus acquired, through the takeover of Sygen International plc, PIC, a company founded by six pork producers in the UK as the Pig Improvement Company in 1962.[5]
Operations
editThe company has three divisions:[6]
- ABS - products for cattle
- PIC - products for pigs
- Genus R&D - management of the research and development pipeline for cattle, pigs and other species.
PIC's pedigree herds sire an estimated 30% of commercially reared pigs.[7]
References
edit- ^ a b "About Us - Our Team". Genus plc. Retrieved 2 August 2023.
- ^ a b c "Annual Report 2023" (PDF). Genus plc. Retrieved 12 February 2024.
- ^ The BSE Inquiry Archived 2008-10-10 at the Wayback Machine
- ^ "Genus agrees to acquire ABS Global". Milwaukee Business Journal. 3 August 1999. Retrieved 1 March 2020.
- ^ "Genus Completes Acquisition Of Sygen". The Pig Site. Archived from the original on 9 February 2012. Retrieved 28 March 2015.
- ^ "Genus". Market Watch. Retrieved 25 March 2018.
- ^ Devlin, Hannah (20 June 2018). "Scientists genetically engineer pigs immune to costly disease". The Guardian. Retrieved 11 December 2021.
External links
edit